



AGENDA

POETIC Winter Meeting

February 28th – March 1st, 2019

Huntsman Cancer Institute/University of Utah
Salt Lake City, Utah

WEDNESDAY, FEBRUARY 27

EVENING SESSION
4:00 PM MT (6:00 PM EST)

**Huntsman Cancer Institute Research South, 6th Floor
Conference Room**

4:00 PM MT (6:00 EST)

BOARD OF DIRECTORS MEETING (Closed Session)

5:00 PM

DINNER
Board of Directors

THURSDAY, FEBRUARY 28

MORNING SESSION
7:30 AM – 1:15 PM

**Huntsman Cancer Institute Research South, 1st Floor
J Willard and Alice S Marriott Foundation Auditorium**

7:15 – 10:15 AM

Shuttle bus service: University Guest House to HCI

7:30 – 8:00 AM

REGISTRATION/BREAKFAST

GREETINGS/INTRODUCTIONS

Nellie Ulrich, PhD, Jon M. and Karen Huntsman Presidential Professor in Cancer Research, Director Comprehensive Cancer Center at Huntsman Cancer Institute, Professor, Department of Population Health Sciences, University of Utah

Richard Lemons, MD, PhD, Division Chief and Medical Director, University of Utah, Huntsman Cancer Institute

Luke Maese, DO, University of Utah, Huntsman Cancer Institute

WELCOME ADDRESS

Tanya Trippett, MD, Memorial Sloan Kettering Cancer Center, Co-Founder and Co-Director, POETIC

8:00 – 8:15 AM

Norman Lacayo, MD, Lucile Packard/Stanford University, Co-Director, POETIC

8:15 – 10:30 AM	KEYNOTE ADDRESS
8:15 – 9:15 AM	Title TBD <i>Kevin Jones, MD, Associate Professor of Orthopedics, Huntsman Institute, University of Utah</i>
9:15 – 10:15 AM	Targeting therapeutic vulnerabilities in RAS-driven cancers <i>Martin McMahon, PhD, Cumming-Presidential Professor of Cancer Biology, Dept. of Dermatology & Senior Director for Preclinical Translation, Huntsman Cancer Institute, University of Utah</i>
10:15 – 10:30 AM	BREAK
10:30 AM – 11:00 AM	TREEHOUSE CHILDHOOD CANCER INITIATIVE Comparative RNA sequencing analysis for identification of cancer driver pathways in childhood cancers <i>Lauren M. Sanders, BA, PhD student, UC Santa Cruz, Human Genomics Institute</i>
11:05 AM – 11:45 AM	DRUG-NEM APPROACH Identifying the Optimal Drug Combinations for the Individual Patient by Accounting for Intratumoral Heterogeneity with Single Cell Resolution <i>Sylvia Pleveritis, PhD, Stanford University (Via Webex)</i>
11:45 AM – 12:15 PM	TOUR OF HUNTSMAN CANCER INSTITUTE
12:15 – 1:15 PM	LUNCH – POINT
AFTERNOON SESSION 1:15 – 5:00 PM	Huntsman Cancer Institute Research South, 1st Floor J Willard and Alice S Marriott Foundation Auditorium
1:15 – 2:15 PM	iMATRIX Trials: Clinical update <i>Stephen Simko, MD, Medical Director Innovative Pediatric Oncology Drug Development, Genentech</i>
2:15 – 3:15 PM	Pre-clinical/Clinical development of PV-10 and an Upcoming Clinical Trial in Pediatric Solid tumors <i>Eric Wachter, PhD, Chief Technology Officer Provectus Biopharmaceuticals, Inc. Aru Narendran, MD, PhD, Alberta Children's Hospital Tanya Trippett, MD, Memorial Sloan Kettering Cancer Center</i>
3:15 – 3:30 PM	BREAK
3:30 – 4:45 PM	PEDIATRIC CANCER THERAPEUTIC MODELING
3:30 – 4:15 PM	Exosomal Delivery of PV-10 <i>David Lyden, MD, PhD, Weill Cornell Medical Center</i>
4:15 – 4:45 PM	Comparative Oncology – Ablation model using PV10 in Dogs with Metastatic Lung Cancer <i>Todd Heaton, MD, Memorial Sloan Kettering Cancer Center Tanya Trippett, MD, Memorial Sloan Kettering Cancer Center</i>

4:45 – 5:00 PM	TRANSITION UPDATE <i>Oby Nwankwo, DrPH, POETIC Research Project Manager, Clinical Research Administration, MSKCC</i> <i>Mary Warren, Director, Clinical Research Multi-Site Compliance, Clinical Research Administration, MSKCC</i>
5:00 – 5:15 PM	COMMON RULE UPDATE <i>Tanya Trippett, MD, Co-Founder and Director POETIC</i> <i>Norman Lacayo, MD, Director, POETIC</i>
5:15 PM	MEETING ADJOURN Shuttle bus service: HCI to University Guest House
7:00 PM	DINNER – STANZA ITALIAN BISTRO AND WINE BAR
6:45 – 10:00 PM	Shuttle bus service: University Guest House to Stanza; Stanza to University Guest House

FRIDAY, MARCH 1

MORNING SESSION 8:00 AM – 1:15 PM	Huntsman Cancer Institute Research South, 1st Floor J Willard and Alice S Marriott Foundation Auditorium
7:45 – 10:45 AM	Shuttle bus service: University Guest House to HCI
8:00 – 9:00 AM	REGISTRATION/BREAKFAST
8:00 – 8:40 AM	<i>PI Meeting (Closed Session) Location HCI South 1A</i> <i>PIs only</i>
9:00 – 10:00 AM	POETIC TRANSLATIONAL GENOMICS PROGRAM <i>David Lyden, MD, PhD, Weill Cornell Medical Center</i> <i>Olga Kovalchuk, MD, PhD, University of Lethbridge</i> <i>Bodour Salhia, PhD, University of Southern California</i>
10:00 – 10:30 AM	<i>Multi-Parallel Molecular and Immunologic Profiling in Relapsed/Refractory Pediatric Tumors – A Multicenter POETIC Biology Study</i> <i>Tanya Trippett, MD, Memorial Sloan Kettering Cancer Center</i> <i>Norman Lacayo, MD, Lucile Packard Children's Hospital</i>
10:30 – 10:45 AM	BREAK
10:45 – 11:15 AM	ACTIVE POETIC TRIALS
10:45 – 11:00 AM	<i>Phase I Study of Carfilzomib, Cyclophosphamide, Etoposide</i> <i>PI: Jessica Boklan, MD, Phoenix Children's Hospital</i>
11:00 – 11:15 AM	<i>Phase I/II Trial of Neratinib in Pediatric Malignancies (Closed Session)</i> <i>PI: Tanya Trippett, MD, Memorial Sloan Kettering Cancer Center</i>

11:15 AM – 12:15 PM **Neoantigen Vaccines for Refractory Childhood Leukemia
Project Plan & Preliminary Data**
Aru Narendran, MD, PhD, Alberta Children's Hospital

LUNCH

12:15 – 1:15 PM **INTERNATIONAL INITIATIVE: INTERNATIONAL CHILDREN'S CANCER
RESEARCH CENTRE IN GHANA**
Tanya Trippett, MD, Memorial Sloan Kettering Cancer Center

**AFTERNOON SESSION
1:15 – 4:00 PM**

**Huntsman Cancer Institute Research South, 1st Floor
J Willard and Alice S Marriott Foundation Auditorium**

1:15 – 2:00 PM

NEUROONCOLOGY INITIATIVES/CONCEPTS

1:15 – 1:30 PM **Overview of DIPG Subtypes and Pre-Clinical Plan for the
ACVR1 Inhibitor**
Cynthia Wetmore, MD, PhD, Phoenix Children's Cancer Center

1:30 – 1:45 PM **Concept for Cobi/Plexiform Neurofibromas**
Amy Smith, MD, Orlando Health

1:45 – 2:00 PM **A Phase I Trial of Loco-regional Infusion of 5'Azacytidine and Oral
Vorinostat in Recurrent/Refractory Hypermethylated Pediatric
Brain Tumors**
Soumen Khatua, MD, MD Anderson Cancer Center

2:00 – 2:15 PM

BREAK

2:15 – 3:15 PM **Amgen Pipeline Presentation**
*Anjali Sharma, MD, Medical Director, Clinical Development, Hematology-
Oncology*
PK Morrow, Head, MCL-1 Program
Greg Friberg, VP, R&D
Lisa Bollinger, VP, Material Health and Pediatric Safety & Regulatory Affairs
Eric Ng, Director, Pediatric Safety & Regulatory Affairs
Tony Wagner, Director, Advocacy Amgen, Inc.

3:15 – 3:45 PM

OUTTAKE

Tanya Trippett, MD, Co-Founder and Director POETIC
Norman Lacayo, MD, Director, POETIC

3:45 PM

ADJOURN

2:00 – 5:00 PM

Shuttle bus service: HCI to University Guest House
